Dashboard
Manage Tickers

HOOKHOOKIPA Pharma Inc.

Nasdaq www.hookipapharma.com


$ 0.93 $ 0.01 (1.34 %)    

Friday, 03-May-2024 14:37:06 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 435.98 $ 8.58 (2.01 %)
DIA $ 386.87 $ 4.54 (1.19 %)
SPY $ 511.25 $ 6.26 (1.24 %)
TLT $ 89.88 $ 0.90 (1.01 %)
GLD $ 212.97 $ -0.17 (-0.08 %)
$ 0.9302
$ 0.93
$ 0.92 x 100
$ 0.00 x 0
$ 0.91 - $ 0.94
$ 0.41 - $ 2.05
324,371
na
92.04M
$ 0.81
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 03-22-2024 12-31-2023 10-K
2 11-09-2023 09-30-2023 10-Q
3 08-10-2023 06-30-2023 10-Q
4 05-11-2023 03-31-2023 10-Q
5 03-15-2023 12-31-2022 10-K
6 11-14-2022 09-30-2022 10-Q
7 08-11-2022 06-30-2022 10-Q
8 05-16-2022 03-31-2022 10-Q
9 03-24-2022 12-31-2021 10-K
10 11-10-2021 09-30-2021 10-Q
11 08-12-2021 06-30-2021 10-Q
12 05-12-2021 03-31-2021 10-Q
13 03-18-2021 12-31-2020 10-K
14 11-12-2020 09-30-2020 10-Q
15 08-13-2020 06-30-2020 10-Q
16 05-14-2020 03-31-2020 10-Q
17 03-19-2020 12-31-2019 10-K
18 11-12-2019 09-30-2019 10-Q
19 08-12-2019 06-30-2019 10-Q
20 05-20-2019 03-31-2019 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

breaking-down-hookipa-pharma-4-analysts-share-their-views
Breaking Down HOOKIPA Pharma: 4 Analysts S...
04/26/2024 12:00:23

hc-wainwright--co-maintains-buy-on-hookipa-pharma-lowers-price-target-to-5
HC Wainwright & Co. Maintains Buy on HOOKI...
04/26/2024 10:55:31

HC Wainwright & Co. analyst Arthur He maintains HOOKIPA Pharma (NASDAQ:HOOK) with a Buy and lowers the price target from...

hookipa-pharma-announced-its-final-pivotal-phase-23-trial-design-for-hb-200-in-combination-with-pembrolizumab-based-on-alignment-with-the-fda
HOOKIPA Pharma Announced Its Final Pivotal...
04/25/2024 11:24:43

why-is-penny-stock-hookipa-pharma-trading-higher-on-wednesday
Why Is Penny Stock HOOKIPA Pharma Trading ...
04/24/2024 14:31:37

HOOKIPA Pharma secures FDA clearance for its innovative HB-700 therapeutic vaccine targeting KRAS-mutated cancers. Learn about ...

hookipa-pharma-shares-are-trading-higher-after-the-company-received-fda-clearance-for-its-ind-application-for-hb-700
HOOKIPA Pharma shares are trading higher a...
04/24/2024 11:51:18

hookipa-pharma-received-fda-clearance-for-its-investigational-new-drug-application-for-hb-700-an-arenaviral-therapeutic-vaccine-for-kras-mutated-cancers
HOOKIPA Pharma Received FDA Clearance For ...
04/24/2024 11:02:36

roches-lymphoma-drug-with-chemo-extends-survival-in-pretreated-patients
Roche's Lymphoma Drug With Chemo Extends S...
04/15/2024 12:56:25

Roche study results show prolonged survival in R/R diffuse large B-cell lymphoma patients treated with Columvi (glofitamab) + G...

hookipa-pharma-announced-that-members-of-its-executive-team-will-host-an-investor-call-summarizing-the-companys-constructive-regulatory-interactions-with-the-us-food--drug-administration-fda-and-the-european-medicines-agency-ema
HOOKIPA Pharma Announced That Members Of I...
04/10/2024 11:10:35

rbc-capital-reiterates-outperform-on-hookipa-pharma-maintains-5-price-target
RBC Capital Reiterates Outperform on HOOKI...
03/25/2024 14:25:13

RBC Capital analyst Brian Abrahams reiterates HOOKIPA Pharma (NASDAQ:HOOK) with a Outperform and maintains $5 price target.

hc-wainwright--co-reiterates-buy-on-hookipa-pharma-maintains-65-price-target
HC Wainwright & Co. Reiterates Buy on HOOK...
03/25/2024 10:25:07

HC Wainwright & Co. analyst Arthur He reiterates HOOKIPA Pharma (NASDAQ:HOOK) with a Buy and maintains $6.5 price target.

hookipa-pharma-q4-earnings-insights
HOOKIPA Pharma: Q4 Earnings Insights
03/22/2024 13:20:05

hookipa-pharma-q4-eps-022-misses-019-estimate-sales-741m-beat-455m-estimate-cash-balance-of-1175m
HOOKIPA Pharma Q4 EPS $(0.22) Misses $(0.1...
03/22/2024 11:03:38

HOOKIPA Pharma (NASDAQ:HOOK) reported quarterly losses of $(0.22) per share which missed the analyst consensus estimate of $(0....

roche-terminates-cancer-drug-pact-with-repare-therapeutics-its-second-walkout-within-a-month
Roche Terminates Cancer Drug Pact With Rep...
02/13/2024 13:43:35

Repare Therapeutics regains global rights to camonsertib (RP-3500) after terminating collaboration with Roche. $40M milestone a...

12-health-care-stocks-moving-in-thursdays-pre-market-session
12 Health Care Stocks Moving In Thursday's...
02/08/2024 13:05:59

12-health-care-stocks-moving-in-thursdays-pre-market-session
12 Health Care Stocks Moving In Thursday's...
02/01/2024 13:06:10

rbc-capital-maintains-outperform-on-hookipa-pharma-lowers-price-target-to-5
RBC Capital Maintains Outperform on HOOKIP...
01/30/2024 15:15:38

RBC Capital analyst Brian Abrahams maintains HOOKIPA Pharma (NASDAQ:HOOK) with a Outperform and lowers the price target from...

roche-walks-away-from-hookipa-pharma-partnered-kras-focused-cancer-deal
Roche Walks Away From HOOKIPA Pharma-Partn...
01/29/2024 17:55:20

HOOKIPA Pharma's strategic focus on HB-200 program for HPV16+ HNSCC, infectious disease cure collaboration with Gilead, and...

12-health-care-stocks-moving-in-mondays-pre-market-session
12 Health Care Stocks Moving In Monday's P...
01/29/2024 13:06:03

hookipa-pharma-updates-business-priorities-and-oncology-partnership-programs
HOOKIPA Pharma Updates Business Priorities...
01/29/2024 13:04:55

HOOKIPA to prioritize clinical development of HB-200 for the treatment of HPV16+ head and neck cancers and Gilead-partnered pro...

abbvie-arch-capital-gilead-sciences-and-a-telecom-giant-on-cnbcs-final-trades
AbbVie, Arch Capital, Gilead Sciences And ...
01/18/2024 14:36:18

On CNBC’s "Halftime Report Final Trades," Rob Sechan of NewEdge Wealth said Gilead Sciences, Inc.

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION